Pharmion signs Vidaza manufacturing pact with Ben Venue Laboratories

By Ted A. Knutson

Washington, Dec. 22 - Pharmion Corp. said it entered into an agreement on Tuesday with Ben Venue Laboratories, Inc. to have Ben Venue make finished sterile dosage forms of Vidaza.

The agreement has an initial term expiring on Dec. 19, 2010, which is subject to automatic renewal for additional two-year terms unless either party informs the other of its intention to let the agreement expire by its terms.

The deal requires Ben Venue to manufacture at least 65% of Pharmion's annual requirements for Vidaza. If Ben Venue fails to do so, Pharmion may elect to use a second source supplier for all or any portion of its requirements.

Financial terms of the agreement were not disclosed.

Vidaza, azacitidine for injectable suspension, is used for the treatment of all five subtypes of Myelodysplastic Syndromes, a bone marrow disorder characterized by the production of abnormally functioning, immature blood cells.

Boulder, Colo.-based Pharmion develops hematology and oncology drugs.

Ben Venue Laboratories is a Bedford, Ohio, pharmaceutical manufacturer.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.